TY  - JOUR
AU  - Vogel-Claussen, Jens
AU  - Lasch, Florian
AU  - Bollmann, Benjamin-Alexander
AU  - May, Katharina
AU  - Kuhlmann, Alexander
AU  - Schmid-Bindert, Gerald
AU  - Kaaks, Rudolf
AU  - Barkhausen, Jörg
AU  - Bohnet, Sabine
AU  - Reck, Martin
TI  - Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography [Design und Rationale der HANSE-Studie: Eine ganzheitliche deutsche Lungenkrebs-Früherkennungs-Studie unter Verwendung von Niedrigdosis-Computertomografie].
JO  - RöFo
VL  - 194
IS  - 12
SN  - 0015-8151
CY  - Stuttgart [u.a.]
PB  - Thieme
M1  - DKFZ-2022-01724
SP  - 1333-1345
PY  - 2022
N1  - 2022 Dec;194(12):1333-1345
AB  - Despite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose computed tomography (LDCT) to reduce mortality, Germany still lacks a national screening program. The German Institute for Quality and Efficiency in Health Care (IQWiG) and the Federal Office for Radiation Protection (BfS) both published positive scientific evaluations recommending a quality-controlled national screening program. IQWiG underlined the importance of a clear risk definition, integrated smoking cessation programs, and quality assurance, highlighting the necessity of procedural optimization. In the HANSE study, former and current smokers aged 55-79 years are assessed for their lung cancer risk by the NELSON and PLCOM2012 risk scores. 5000 high-risk participants, defined as PLCOM2012 6-year risk ≥ 1.58 
LB  - PUB:(DE-HGF)16
C6  - pmid:35917826
DO  - DOI:10.1055/a-1853-8291
UR  - https://inrepo02.dkfz.de/record/181016
ER  -